Withdrawn
Acalabrutinib, bortezomib and ibrutinib for treating mantle cell lymphoma
Condition
Blood and Immune System
Cancer
2 January 2024
Published on 12 Jul 2022
Last Updated on 02 Jan 2024
Acalabrutinib, bortezomib and ibrutinib for treating mantle cell lymphoma Guidance is outdated and has been withdrawn on 2 Jan 2024.
The Plain English Summary (PES) has been updated on 2 Jan 2024.
PES Treatments for mantle cell lymphoma (Updated 2 Jan 2024) [PDF, 150 KB]